References
1)World Health Organization HO (2020) Coronavirus disease 2019 (COVID-19) situation report Available fromhttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.
2)Lin L, Lu L, et al. (2020) Hypothesis for potential pathogenesis of Sars-CoV-2 infection a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect.
3)Zou Q, Zheng S et al. Influenza A-associated severe pneumonia in hospitalized patients: risk factors and NAI treatments. Int J Infect Dis 2020.
4)Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet 2020.
5)Stefan R Bornstein et al. Practical recommendations for the management of diabetes in patients with COVID-19 Lancet Diabetes Endocrinol 2020.
6)Hoffmann M, Kleine-Weber H et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020.
7)Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol Cell Endocrinol 2009.
8)Yang JK, Lin SS et al. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetol 2010.
9)Raj VS, Mou H et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013.
10)Li K, Wohlford-Lenane CL, Channappanavar R et al. Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci USA 2017.
11)Fan C, Wu X et al. A Human DPP4- Knockin Mouse’s Susceptibility to Infection by Authentic and Pseudotyped MERS-CoV. Viruses 2018.
12)Yang W, Cai X et al. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
Diabetes Metab Res Rev 2016.
13)Raj VS, Mou H et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature (2013)
14)Iacobellis G. COVID-19 and diabetes: can DPP4 inhibition play a role? DiabetesResClinPract (2020).